Table 2.

Differences in efficacy of EGFR-TKI therapy in females and males by subgroup.

Subgroups		Number of trials	Pooled interaction HR	P-interaction
Overall		21	0.95 (0.87–1.04)	0.30
EGFR situation	Unknown	13	0.94 (0.85–1.03)	0.19
	Wild-type	3	1.06 (0.60–1.89)	0.83
	Mutation	5	1.02 (0.78–1.34)	0.86
Lines of therapy	>1	13	0.94 (0.84–1.05)	0.26
	1	8	0.98 (0.84–1.15)	0.82
EGFR-TKI intervention	Gefitinib	6	0.97 (0.84–1.11)	0.64
	Erlotinib	12	0.93 (0.82–1.07)	0.31
	Others	3	0.98 (0.74–1.30)	0.91
Control treatment	Placebo	6	0.86 (0.75–1.00)	0.04
	Chemotherapy	13	1.01 (0.89–1.14)	0.89
	Others	2	1.21 (0.77–1.91)	0.42